The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...

Every year, about 85,000 Americans are diagnosed with bladder cancer. While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, ...

The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was ...

Gross hematuria in a younger adult prompted rapid urologic evaluation, underscoring that bladder cancer can present before ...

Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...

Combination significantly improved disease-free survival in phase III trial ...

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...